Columbia University BioWorks
BioWorks 8: AI-Driven Drug Discovery with Alex Zhavoronkov
May 20, 2023
In this conversation, Alex Zhavoronkov, founder and CEO of Insilico Medicine, dives into the transformative power of AI in drug discovery, discussing everything from target identification to speeding up clinical trials. He shares his unique journey from computer science to biotech, emphasizing the vital role of deep learning in tackling age-related diseases. Alex introduces the concept of 'pandaomics' for understanding gene networks and highlights the importance of interdisciplinary teams in innovation. He also shares insights on personal growth and the future of biotech.
58:30
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Alex Zhavoronkov discusses his transition from computer science to biotech, emphasizing the influence of AI in accelerating drug research and development.
- He highlights the significance of focusing on aging research in drug discovery, as understanding it can lead to breakthroughs in age-related disease treatment.
Deep dives
Overview of Alex Zhavarankov's Background and Career
Alex Zhavarankov, the founder and CEO of Ensilico Medicine, discusses his unique journey from a background in computer science to the biotech industry. He emphasizes his accidental entry into artificial intelligence (AI) for drug discovery, which stemmed from a lifelong passion for aging research. Through his educational experiences in Canada and extensive work in semiconductor companies, Alex eventually pursued advanced studies in biotechnology and mathematics. His career pivoted towards AI during the deep learning revolution, ultimately leading to the establishment of Ensilico Medicine, which focuses on leveraging AI for accelerated drug discovery.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
